Inhaled Levofloxacin Beneficial in CF Patients with Pseudomonas aeruginosa Infection

In a placebo-controlled trial, inhaled levofloxacin (240 mg twice daily) significantly reduced sputum P. aeruginosa density and improved pulmonary function.

Among patients with cystic fibrosis (CF), chronic infection with Pseudomonas aeruginosa (PA) is associated with a more rapid clinical decline. Delivering antibiotics by aerosol can yield high pulmonary concentrations while limiting systemic exposure. In a manufacturer-supported, multicenter trial, researchers assessed the efficacy, safety, and tolerability of MP-376, an aerosolized formulation of levofloxacin that has activity against PA and is not inactivated in CF sputum.

A total of 151 adult CF patients with chronic PA infection were randomized to receive a 28-day course of either inhaled placebo or MP-376 at one of three dosing regimens (120 mg daily, 240 mg daily, or 240 mg twice daily). At baseline, 62% of the PA isolates were resistan…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Inhaled Levofloxacin Beneficial in CF Patients with Pseudomonas aeruginosa Infection

Topics

Reviewing Author